COMP <GO>

PLRX vs CTOR // 10Y YIELD & FRED MACRO BETA

Pliant Therapeutics Inc. (NASDAQ) VS. Citius Oncology Inc. (NASDAQ) • 15-METRIC TALLY: PLRX 3 — CTOR 0

■ METRIC PARITY

LAST: $0.84 (-2.29%) • MKT CAP: $53.2M

macro-sensitivity

—

LAST: $0.59 (+7.24%) • MKT CAP: $51.5M

macro-sensitivity

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLRX VS. CTOR) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	PLRX	CTOR	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	-11.16%	—	TIE	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	2/9	1/9	+1.00	PLRX	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	35.3	31.0	+4.30	PLRX	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$53.2M	$51.5M	$1.7M	PLRX	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	PLRX REV	CTOR REV	PLRX GROSS %	CTOR GROSS %	PLRX FCF	CTOR FCF
FY 2025	$437.8M	$65.9M	—	—	-$128.7M	-$5.5M
FY 2024	$639.4M	$57.6M	—	—	-$159.4M	$126.4K
FY 2023	$1.6M	$2.8M	—	—	-$116.4M	-$601.3K

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

PLRX // BETA —

CTOR // BETA —